• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Dyadic International Inc.

    2/14/22 3:11:46 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    SC 13G 1 sc13g08706dyai_02142022.htm THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    Dyadic International, Inc.

     (Name of Issuer)

    Common Stock, $0.001 par value

     (Title of Class of Securities)

    26745T101

     (CUSIP Number)

    December 31, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☒  Rule 13d-1(b)

       ☐  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 26745T101

     

      1   NAME OF REPORTING PERSON  
             
            BANDERA PARTNERS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,566,908  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,566,908  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,566,908  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            IA, OO  

      

    2

    CUSIP No. 26745T101

      1   NAME OF REPORTING PERSON  
             
            GREGORY BYLINSKY  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,566,908  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,566,908  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,566,908  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    3

    CUSIP No. 26745T101

     

      1   NAME OF REPORTING PERSON  
             
            JEFFERSON GRAMM  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,566,908  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,566,908  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,566,908  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    4

    CUSIP No. 26745T101

    Item 1(a).Name of Issuer:

     

    Dyadic International, Inc. (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    140 Intracoastal Pointe Drive, Suite 404

    Jupiter, FL 33477

     

    Item 2(a).Name of Person Filing:

    This statement is filed by Bandera Partners LLC, a Delaware limited liability company (“Bandera Partners”), Gregory Bylinsky and Jefferson Gramm. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Bandera Partners, Mr. Bylinsky and Mr. Gramm are filing this Statement with respect to 1,566,908 shares of Common Stock (the “Master Fund’s Shares”) directly held by Bandera Master Fund L.P., a Cayman Islands exempted limited partnership (“Bandera Master Fund”).

     

    Bandera Partners is the investment manager of Bandera Master Fund and may be deemed to have beneficial ownership over the Master Fund’s Shares by virtue of the sole and exclusive authority granted to Bandera Partners by Bandera Master Fund to vote and dispose of the Master Fund’s Shares.

     

    Mr. Bylinsky and Mr. Gramm are Managing Partners, Managing Directors and Portfolio Managers of Bandera Partners.

    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares (as defined below) reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein. Without limiting the foregoing sentence, Bandera Master Fund specifically disclaims beneficial ownership of the Master Fund’s Shares by virtue of its inability to vote or dispose of such Shares.

    Item 2(b).Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is 50 Broad Street, Suite 1820, New York, New York 10004.

    Item 2(c).Citizenship:

    Bandera Partners is organized under the laws of the State of Delaware. Each of Messrs. Bylinsky and Gramm is a citizen of the United States of America.

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.001 par value per share (the “Shares”).

    Item 2(e).CUSIP Number:

    26745T101

    5

    CUSIP No. 26745T101

    Item 3.If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
        /  / Not Applicable
      (a) /  / Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
      (b) /  / Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) /  / Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) /  / Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) /X/ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).
      (f) /  / Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
      (g) /  / Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).
      (h) /  / Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) /  / Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
      (j) /  / Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
      (k) /  / Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

     

    Item 4.Ownership.

    All ownership information reported in this Item 4 is as of the close of business on December 31, 2021.

    Bandera Partners LLC

    (a)Amount beneficially owned:

    1,566,908 Shares

    (b)Percent of class:

    5.6% (based on 28,079,157 Shares outstanding as of November 9, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021)

    6

    CUSIP No. 26745T101

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    1,566,908 Shares

    (ii)Shared power to vote or to direct the vote

    0 Shares

    (iii)Sole power to dispose or to direct the disposition of

    1,566,908 Shares

    (iv)Shared power to dispose or to direct the disposition of

    0 Shares

    Gregory Bylinsky

    (a)Amount beneficially owned:

    1,566,908 Shares

    (b)Percent of class:

    5.6% (based on 28,079,157 Shares outstanding as of November 9, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021)

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    0 Shares

    (ii)Shared power to vote or to direct the vote

    1,566,908 Shares

    (iii)Sole power to dispose or to direct the disposition of

    0 Shares

    (iv)Shared power to dispose or to direct the disposition of

    1,566,908 Shares

    7

    CUSIP No. 26745T101

    Jefferson Gramm

    (a)Amount beneficially owned:

    1,566,908 Shares

    (b)Percent of class:

    5.6% (based on 28,079,157 Shares outstanding as of November 9, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021)

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    0 Shares

    (ii)Shared power to vote or to direct the vote

    1,566,908 Shares

    (iii)Sole power to dispose or to direct the disposition of

    0 Shares

    (iv)Shared power to dispose or to direct the disposition of

    1,566,908 Shares

    Item 5.Ownership of Five Percent or Less of a Class.

    Not applicable.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The right to receive dividends from, or the proceeds from the sale of, the Master Fund’s Shares is held by Bandera Master Fund, a private investment fund for which Bandera Partners serves as investment manager. Bandera Partners, Mr. Bylinsky and Mr. Gramm disclaim beneficial ownership of the Master Fund’s Shares reported in this statement pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1.

    8

    CUSIP No. 26745T101

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    9

    CUSIP No. 26745T101

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2022

     

      BANDERA PARTNERS LLC
       
      By:

    /s/ Gregory Bylinsky

        Name: Gregory Bylinsky
        Title: Managing Director
           
           
      By:

    /s/ Gregory Bylinsky

        Name: Gregory Bylinsky
           
           
      By:

    /s/ Jefferson Gramm

        Name: Jefferson Gramm

     

    10

      

    Get the next $DYAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/13/24 4:41:59 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/1/24 4:15:18 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      3/14/23 4:01:06 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Financials

    Live finance-specific insights

    See more

    $DYAI
    Leadership Updates

    Live Leadership Updates

    See more

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

      JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85

      3/12/25 4:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Appoints Doug Pace to Its Executive Leadership Team

      JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

      10/9/23 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Appoints Chief Business Officer to Executive Leadership Team

      JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

      11/9/21 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Present at World Vaccine Congress | Washington

      JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, D.C.April 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40

      4/16/25 2:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kaye Jack exercised 30,000 shares at a strike of $1.33 and covered exercise/tax liability with 27,517 shares, increasing direct ownership by 4% to 59,649 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      3/7/25 4:07:16 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herbst Seth exercised 25,000 shares at a strike of $0.97, increasing direct ownership by 16% to 180,759 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/8/25 5:19:28 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kaye Jack converted options into 23,585 shares, increasing direct ownership by 70% to 57,166 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/7/25 6:08:20 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    SEC Filings

    See more
    • Dyadic International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      5/5/25 5:03:31 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Dyadic International Inc.

      DEFA14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:33:14 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Dyadic International Inc.

      DEF 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      4/29/25 4:32:22 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dyadic International downgraded by Dawson James

      Dawson James downgraded Dyadic International from Buy to Neutral

      7/18/22 9:59:51 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

      HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

      12/17/21 6:17:22 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care